A Risk-Benefit Assessment of Levofloxacin in Respiratory, Skin and Skin Structure, and Urinary Tract Infections

ISSN： 0114-5916

Source： Drug Safety, Vol.24, Iss.3, 2001-01, pp. : 199-222

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Levofloxacin: Its Use in Infections of the Respiratory Tract, Skin, Soft Tissues and Urinary Tract

By Langtry H.D. Lamb H.M.

Drugs, Vol. 56, Iss. 3, 1998-09 ,pp. : 487-515

Adis International

Access to resources Recommend Favorite

Ertapenem as effective as other antibacterials in treating intra-abdominal, skin, urinary, respiratory tract and acute pelvic infections

By Adis International Limited

Drugs & Therapy Perspectives, Vol. 20, Iss. 7, 2004-07 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

Carbapenems in Serious Infections: A Risk-Benefit Assessment

By Ragnar Norrby S.

Drug Safety, Vol. 22, Iss. 3, 2000-03 ,pp. : 191-194

Adis International

Access to resources Recommend Favorite

Risk-Benefit Assessment of Therapies for Mycobacterium avium Complex Infections

By Griffith D.E.

Drug Safety, Vol. 21, Iss. 2, 1999-08 ,pp. : 137-152

Adis International

Access to resources Recommend Favorite

Cefditoren pivoxil: a guide to its use in the treatment of bacterial infections of the respiratory tract or skin and skin structures

By Adis International Limited

Drugs & Therapy Perspectives, Vol. 24, Iss. 9, 2008-09 ,pp. : 5-8

Adis International

Access to resources Recommend Favorite